|
Categories |
|
Pharmaceuticals |
|
|
Biotechnology
Cancer
Consumer
Customer
Relationship Management
Drug
Delivery
eHealthcare
Pharma
eHealthcare
Physician
Generics
Healthcare
Medical
Devices
OTC
Pharmaceuticals
Pharmaceuticals
Pharmacoeconomics
Therapeutic
Areas:
- Cardiovascular
- Central
Nervous System
- Immune
Disorders and Inflammation
- Infectious
Diseases
- Oncology
-
Women'sHealth
|
|
|
1- Ipsen: PharmaVitae Profile 2005 11-Nov-2005
This company analysis examines the market position and future outlook for Ipsen. The profile encompasses global and US specific company strategy, portfolio and pipeline analysis and assessment of financial performance, with US, rest of world and global forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
2- Boehringer Ingelheim: PharmaVitae Profile 2005 16-Nov-2005
This analysis examines the current position and future outlook for Boehringer Ingelheim in the pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information..
------------------------------------------------------------------------------------------------------------------------- |
3- Wyeth: PharmaVitae Profile 2005 16-Nov-2005
This Company Analysis examines the current position and future outlook for Wyeth in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
4- UCB: PharmaVitae Profile 2005 16-Nov-2005
This analysis examines the current position and future outlook for UCB in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
5- Merck & Co: PharmaVitae Profile 2005 17-Nov-2005
This company analysis examines the current position and future outlook for Merck & Co in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
6- Biogen Idec: PharmaVitae Profile 2005 22-Nov-2005
This Company Analysis examines the current position and future outlook for Biogen IDEC in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
7- PharmaVitae 2005: Novo Nordisk Global Analysis 20-Oct-2005
This analysis examines the current position and future outlook for Novo Nordisk in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
8- Novo Nordisk: PharmaVitae Profile 2005 20-Oct-2005
This analysis examines the current position and future outlook for Novo Nordisk in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
9- PharmaVitae 2005: GlaxoSmithKline Global Analysis 17-Oct-2005
This analysis examines the current position and future outlook for GSK in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
10- GlaxoSmithKline: PharmaVitae Profile 2005 17-Oct-2005
This analysis examines the current position and future outlook for GSK in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information..
------------------------------------------------------------------------------------------------------------------------- |
11- Rx-To-OTC Switching Strategies: Lifecycle management and building brand equity in the US, EU & ROW 05-Oct-2005
------------------------------------------------------------------------------------------------------------------------- |
12- PharmaVitae 2005: Pfizer Global Analysis 03-Oct-2005
This analysis examines the current position and future outlook for Pfizer in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
13- PharmaVitae 2005: Pfizer Global and US Analysis 03-Oct-2005
This analysis examines the current position and future outlook for Pfizer in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
14- PharmaVitae 2005: Serono Global & US Analysis 16-Sep-2005
This analysis examines the current position and future outlook for Serono in the biotechnology sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
15- PharmaVitae 2005: Serono Global Analysis 16-Sep-2005
This analysis examines the current position and future outlook for Serono in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
16- PharmaVitae 2005: Sanofi-Aventis Global Analysis 06-Sep-2005
This analysis examines the current position and future outlook for Sanofi-Aventis in the ethical pharmaceutical sector. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
17- PharmaVitae 2005: Sanofi-Aventis Global and US Analysis 06-Sep-2005
This analysis examines the current position and future outlook for Sanofi-Aventis in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
18- PharmaVitae 2005: Novartis Global Analysis 06-Sep-2005
This analysis examines the current position and future outlook for Novartis in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
19- PharmaVitae 2005: Novartis Global & US Analysis 06-Sep-2005
This analysis examines the current position and future outlook for Novartis in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
20- PharmaVitae 2005: Chiron Global Analysis 06-Sep-2005
This analysis examines the current position and future outlook for Chiron in the biotechnology sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
21- PharmaVitae 2005: Chiron Global and US Analysis 06-Sep-2005
This analysis examines the current position and future outlook for Chiron in the biotechnology sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
22- PharmaVitae 2005: King Pharmaceuticals Global Analysis 06-Sep-2005
This analysis examines the current position and future outlook for King in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
23- PharmaVitae 2005: King Pharmaceuticals Global and US Analysis 06-Sep-2005
This analysis examines the current position and future outlook for King in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
24- PharmaVitae 2005: Forest Global Analysis 23-Aug-2005
This company analysis examines Forest's current position and future outlook in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis, and an assessment of financial performance, with global forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
25- PharmaVitae 2005: Forest Global and US Analysis 23-Aug-2005
This company analysis examines Forest's current market position and future outlook. The profile encompasses global and US specific company strategy, portfolio and pipeline analysis, and an assessment of financial performance, with sales forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
26- PharmaVitae 2005: Almirall Global Analysis 10-Aug-2005
This company analysis examines Almirall's market position and future outlook. The profile encompasses global company strategy, portfolio and pipeline analysis, and an assessment of financial performance, with forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
27- PharmaVitae 2005: Almirall Global and US Analysis 10-Aug-2005
This analysis examines the market position and future outlook for Almirall. The profile encompasses global and US specific company strategy, portfolio and pipeline analysis and assessment of financial performance, with US, rest of world and global forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
28- PharmaVitae 2005: Altana Global and US Analysis 03-Aug-2005
This company analysis examines Altana's market position and future outlook. The profile encompasses global and US specific company strategy, portfolio and pipeline analysis, and an assessment of financial performance, with US, rest of world and global forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
29- PharmaVitae 2005: Altana Global Analysis 03-Aug-2005
This company analysis examines Altana's market position and future outlook. The profile encompasses global company strategy, portfolio and pipeline analysis, and an assessment of financial performance, with forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
30- PharmaVitae 2005: MedImmune Global and US Analysis 27-Jul-2005
This analysis examines the market position and future outlook for MedImmune. The profile encompasses global and US specific company strategy, portfolio and pipeline analysis and assessment of financial performance, with US, rest of world and global forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
31- PharmaVitae 2005: MedImmune Global Analysis 27-Jul-2005
This analysis examines the market position and future outlook for MedImmune. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with global forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
32- PharmaVitae 2005: Genzyme Global and US Analysis 22-Jul-2005
This analysis examines the current position and future outlook for Genzyme in the biotechnology sector. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information..
------------------------------------------------------------------------------------------------------------------------- |
33- PharmaVitae 2005: Genzyme Global Analysis 21-Jul-2005
This analysis examines the current position and future outlook for Genzyme in the biotechnology sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
34- PharmaVitae 2005: Johnson & Johnson Global Analysis 15-Jul-2005
This Analysis examines the current position and future outlook for J&J in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
35- PharmaVitae 2005: Johnson & Johnson Global & US Analysis 15-Jul-2005
This Analysis examines the current position and future outlook for J&J in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
36- PharmaVitae 2005: Shire Global Analysis 12-Jul-2005
This analysis examines the current position and future outlook for Shire Pharmaceuticals in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
37- PharmaVitae 2005: Shire Global & US Analysis 12-Jul-2005
This analysis examines the current position and future outlook for Shire Pharmaceuticals in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
38- Drug Safety in the Post-Vioxx Era: New legislation, regulation and strategy in Europe and the US 01-Jul-2005
The new report, Drug Safety in the Post-Vioxx Era: New legislation, regulation and company strategies in Europe and the US, examines the actions taken by legislative and regulatory bodies in response to recent drug safety concerns surrounding the COX-2 inhibitors and antidepressants. The report also analyzes the different management, marketing and technological strategies companies are pursuing to ensure the safety of their products, and provides predictions for the future of drug safety regulation in the US and EU.
------------------------------------------------------------------------------------------------------------------------- |
39- PharmaVitae 2005: Roche Global Analysis 22-Jun-2005
This analysis examines the current position and future outlook for Roche in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
40- PharmaVitae 2005: Roche Global and US Analysis 22-Jun-2005
This analysis examines the current position and future outlook for Roche in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
------------------------------------------------------------------------------------------------------------------------- |
40- PharmaVitae 2004: Mitsubishi Pharma Global & US Analysis 9-Jun-2005
This analysis examines the current position and future outlook for Mitsubishi Pharma in the Japanese pharmaceutical sector. It encompasses company strategy, comparative portfolio and pipeline analysis and assessment of financial performance, providing 1-7 year sales forecasts for key drugs.
-------------------------------------------------------------------------------------------------------------------------
|
41- Stakeholder Insight: Asthma - Combination
Therapy Appropriate for Everyone?
7-Jan-2005
Detailed analysis of asthma
epidemiology, treatment practice and key developmental compounds
across the seven major markets based on a survey of 180 physicians,
combined with primary research directed at pulmonologists.
-------------------------------------------------------------------------------------------------------------------------
|
48- Optimizing Licensing Strategies for the 21st
Century: Creating Win-Win Pharma & Biotech
Licensing 22-Dec-2004
A recommendation-driven strategic evaluation of
alliance portfolio management in the pharmaceutical sector and the
mechanisms underpinning successful early and late stage licensing
deals.
-------------------------------------------------------------------------------------------------------------------------
|
49- Inflammatory Bowel Disease - Efficacy and
Compliance Key to Maximizing Patient Share
22-Dec-2004
Analysis of treatment of IBD in
seven major markets. Includes unique data from Stakeholder Insight
survey of 180 physicians who treat IBD. Examines physician
prescribing patterns and perceptions, and why physicians prescribe
particular therapies.
-------------------------------------------------------------------------------------------------------------------------
|
50- Global Generics Guide 3rd Edition:
Benchmarking Generics Company Capabilities and
Strategy 21-Dec-2004
In-depth analysis and insight into the current and
future competitive environment within the generics markets of the
US, UK, Germany, France, Spain and Italy, based on comprehensive
analysis of the capabilities and portfolios of the leading players.
-------------------------------------------------------------------------------------------------------------------------
|
51- Stakeholder Opinions: HIV Vaccines - The
Emperor Has No Clothes 21-Dec-2004
A comprehensive overview of current strategies and
issues surrounding the research, development and potential adoption
of a potential HIV vaccine.
-------------------------------------------------------------------------------------------------------------------------
|
52- Benchmarking Best Practice at Patent Expiry in
the US - Maximizing ROI of Late-Stage Lifecycle
21-Dec-2004
Quantitative analysis of the
impact of patent expiry, combined with in-depth insight into the
regulatory and cost-containment policies shaping the post-patent
market, competitive landscape and key stakeholder opinions in the US
market.
-------------------------------------------------------------------------------------------------------------------------
|
53- Benchmarking
Best Practice at Patent Expiry in Europe - Maximizing Return on
Investment of Late-Stage Lifecycle Management 13-Dec-2004
Quantitative analysis of the impact of patent expiry,
combined with in-depth insight into the regulatory and
cost-containment policies shaping the post-patent market,
competitive landscape and key stakeholder opinions in the five major
EU markets.
-------------------------------------------------------------------------------------------------------------------------
|
54- Pipeline Insight: Non-insulin Antidiabetics -
Three New Classes Compete for Market Control
1-Dec-2004
In-depth, critical evaluation of
the antidiabetic compounds in development. It assesses the
commercial prospects for the launch of innovative new products
against the level of existing unmet needs in this market.
-------------------------------------------------------------------------------------------------------------------------
|
55- PharmaVitae 2004: Yamanouchi Global and US
Analysis 22-Nov-2004
Global analysis of Yamanouchi's strategy, marketed
portfolio, pipeline potential and financial position in 2004.
-------------------------------------------------------------------------------------------------------------------------
|
56- PharmaVitae
2004: Yamanouchi Global Analysis 22-Nov-2004
Global analysis of Yamanouchi's strategy, marketed
portfolio, pipeline potential and financial position in 2004.
-------------------------------------------------------------------------------------------------------------------------
|
57- Critical Success Factors at Product Launch:
Evaluating the Influencers of First-Year Market
Share 19-Nov-2004
Analysis of the key product, market, company and
promotional factors influencing the success of product launches
between 1999 and 2003 across Europe and the US.
-------------------------------------------------------------------------------------------------------------------------
|
58- PharmaVitae 2004: Solvay Global and US
Analysis 18-Nov-2004
Global and US focused analysis of Solvay's strategy,
marketed portfolio, pipeline potential and financial position in
2004.
-------------------------------------------------------------------------------------------------------------------------
|
59- PharmaVitae 2004: Solvay Global
Analysis 18-Nov-2004
Global analysis of Solvay's strategy, marketed
portfolio, pipeline potential and financial position in 2004.
-------------------------------------------------------------------------------------------------------------------------
|
60- PharmaVitae 2004: Roche Global and US
Analysis 9-Nov-2004
Global and US focused analysis of Roche's strategy,
marketed portfolio, pipeline potential and financial position in
2004.
-------------------------------------------------------------------------------------------------------------------------
|
61- PharmaVitae 2004: Roche Global
Analysis 9-Nov--2004
Global analysis of Roche's strategy, marketed
portfolio, pipeline potential and financial position in 2004.
-------------------------------------------------------------------------------------------------------------------------
|
62- Commercial Insight: Asthma and COPD - Control
is the Goal 21-Oct-2004
An analysis of the asthma/COPD therapeutic market
based on IMS Health sales for full year 2003. Global and country
level forecasts to 2014 for the leading branded products with
country specific opportunities and threats identified and discussed.
-------------------------------------------------------------------------------------------------------------------------
|
63- Stakeholder Opinions: Non-Hodgkin's Lymphoma -
Immunotherapy Stimulates the Market
19-Oct-2004
Key issues in NHL pharmacotherapy,
including epidemiological and treatment controversies, advancements
in disease classification and diagnosis, and novel NHL therapies in
the developmental pipeline.
-------------------------------------------------------------------------------------------------------------------------
|
64- Rigel's Allergic Rhinitis Candidate -
R112 19-Oct-2004
Analysis of the commercial prospects for Rigel's phase
II allergic rhinitis candidate, R112, with opinion leader views on
the novel mechanism and likely future direction of this allergic
rhinitis treatment.
-------------------------------------------------------------------------------------------------------------------------
|
65- PharmaVitae 2004: Wyeth Global and US
Analysis 18-Oct-2004
Global and US focused analysis of Wyeth's strategy,
marketed portfolio, pipeline potential and financial position in
2004.
-------------------------------------------------------------------------------------------------------------------------
|
66- PharmaVitae 2004: Wyeth Global
Analysis 18-Oct-2004
Global analysis of Wyeth's strategy, marketed
portfolio, pipeline potential and financial position in 2004.
-------------------------------------------------------------------------------------------------------------------------
|
67- PharmaVitae 2004: Takeda Global
Analysis 18-Oct-2004
Global analysis of Takeda's strategy, marketed
portfolio, pipeline potential and financial position in 2004.
-------------------------------------------------------------------------------------------------------------------------
|
68- PharmaVitae 2004: Takeda Global & US
Analysis 18-Oct-2004
Global and US focused analysis of Takeda's strategy,
marketed portfolio, pipeline potential and financial position in
2004.
-------------------------------------------------------------------------------------------------------------------------
|
69- PharmaVitae 2004: Fujisawa Global
Analysis 18-Oct-2004
Global analysis of Fujisawa's strategy, marketed
portfolio, pipeline potential and financial position in 2004.
-------------------------------------------------------------------------------------------------------------------------
|
70- PharmaVitae 2004: Fujisawa Global & US
Analysis 18-Oct-2004
Global and US focused analysis of Fujisawa's strategy,
marketed portfolio, pipeline potential and financial position in
2004.
-------------------------------------------------------------------------------------------------------------------------
|
71- Commercial and Pipeline Perspectives: Upper GI
Disorders - Life Cycle Management Key as Generics and OTC Threaten
Growth 4-Oct-2004
Analysis of R&D products for GERD/PUD in seven
major markets. Includes opinion leader insight on the future
direction of the GERD/PUD market. Examines current GERD/PUD market
trends and forecasts sales of marketed and pipeline products.
-------------------------------------------------------------------------------------------------------------------------
|
72- PharmaVitae 2004: Menarini Global
Analysis
14-July-2004
Global analysis of Menarini's strategy, marketed
portfolio, pipeline potential and financial position in
2004.
------------------------------------------------------------------------------------------------------------------------- |
73- PharmaVitae 2004: Chiron Global & US
Analysis 14-July-2004
Global and US focused
analysis of Chiron's strategy, marketed portfolio, pipeline
potential and financial position in 2004.
------------------------------------------------------------------------------------------------------------------------- |
74- PharmaVitae 2004: Menarini Global
Analysis 14-July-2004
Global analysis of
Menarini's strategy, marketed portfolio, pipeline potential and
financial position in 2004.
------------------------------------------------------------------------------------------------------------------------- |
75- PharmaVitae 2004: MedImmune Global
Analysis 14-July-2004
Global analysis of
MedImmune's strategy, marketed portfolio, pipeline potential and
financial position in 2004.
------------------------------------------------------------------------------------------------------------------------- |
76- PharmaVitae 2004: Bristol-Myers Squibb Global
Analysis 14-July-2004
Global analysis of
Bristol-Myers Squibb's strategy, marketed portfolio, pipeline
potential and financial position in 2004.
------------------------------------------------------------------------------------------------------------------------- |
77-PharmaVitae 2004: Bristol-Myers Squibb Global
& US Analysis 14-July-2004
Global and US focused analysis of Bristol-Myers
Squibb's strategy, marketed portfolio, pipeline potential and
financial position in 2004.
------------------------------------------------------------------------------------------------------------------------- |
78-PharmaVitae 2004: Menarini Global & US
Analysis 14-July-2004
Global and US focused
analysis of Menarini's strategy, marketed portfolio, pipeline
potential and financial position in 2004.
------------------------------------------------------------------------------------------------------------------------- |
79-PharmaVitae 2004: Amgen Global
Analysis 06-July-2004
Global analysis of
Amgen's strategy, marketed portfolio, pipeline potential and
financial position in 2004.
------------------------------------------------------------------------------------------------------------------------- |
80-PharmaVitae 2004: Amgen Global and US
Analysis 06-July-2004
Global and US focused
analysis of Amgen's strategy, marketed portfolio, pipeline potential
and financial position in 2004.
------------------------------------------------------------------------------------------------------------------------- |
81-PharmaVitae 2004: Pfizer Global
Analysis 05-July-2004
Global analysis of
Pfizer's strategy, marketed portfolio, pipeline potential and
financial position in 2004.
------------------------------------------------------------------------------------------------------------------------- |
82-Growth Strategies in Generics: The impact on
branded pharmaceuticals
01-July-2004
The report gives a detailed analysis of the impact of
new legislation, the strategies of the key players and market
pressures on the generic and branded drug
sectors.
------------------------------------------------------------------------------------------------------------------------- |
83- PharmaVitae 2004: Celltech Global
Analysis 23-June-2004
(Pharmaceutical)
Global analysis of Celltech's
strategy, marketed portfolio, pipeline potential and financial
position in 2004.
------------------------------------------------------------------------------------------------ |
84- Biogenerics: Drivers and Resistors of Market
Development 26-Apr-2004
Analysis of the status of biogenerics market
development in the US and EU, focusing on regulatory issues,
barriers to entry, market potential and strategies of the likely key
players.
-------------------------------------------------------------------------------------------------------------------------
|
85- Addressing Pharma’s R&D
Productivity Crisis: Technological and Strategic Initiatives to
Improve Core Drug Discovery Capabilities 20-Apr-2004
Analysis of
the R&D crisis facing the pharmaceutical industry, examining the
factors underlying poor productivity, including the technological
and strategic opportunities available for strengthening core drug
discovery expertise and productivity.
-------------------------------------------------------------------------------------------------------------------------
|
86- The Japanese Pharmaceutical Companies Outlook: An
analysis of key players and growth strategies Mar-2004
An analysis of key
players and growth strategies evaluates the strengths and weaknesses
of the top 10 Japanese pharmaceutical firms' strategic and financial
positions, marketed portfolios and pipeline
compounds.
-------------------------------------------------------------------------------------------------------------------------
|
87- Winning Pharmaceutical R&D Strategies: Boosting
profitability through improvements in portfolio management,
licensing and clinical trials
Mar-2003
The report
helps you devise strategies to overcome inefficiencies in your
R&D process and generate greater returns on
investment.
-------------------------------------------------------------------------------------------------------------------------
|
88- The Pharmaceutical Parallel Trade Outlook: Challenges
to pharmaceutical companies across Europe and the US Feb-2004
The
Pharmaceutical Parallel Trade Outlook: Challenges to pharmaceutical
companies across Europe and the US, analyzes parallel trade market
dynamics, reviews the latest regulatory and pricing controls in the
EU and US, and assesses the drivers and resistors of parallel trade
in 2004.
-------------------------------------------------------------------------------------------------------------------------
|
89-
Commercial Opportunities from an Aging Population:
Epidemiology, market and pipeline analysis across seven major
indications
Feb-2004
ill increase and drugs will be used for longer. This
report analyzes commercial opportunities within the ‘gray market’
and shows how companies can meet these needs and keep company
profits high.
-------------------------------------------------------------------------------------------------------------------------
|
90- Commercial Perspectives: Anti-dyslipidemics - A tale
of two launches
30-Jan-2004
This
report, based on IMS Health global sales data for 2001 and 2002,
provides detailed product profiles for the leading
anti-dyslipidemics and explores the impact of key events on both
current and future market
dynamics.
-------------------------------------------------------------------------------------------------------------------------
|
91- Pipeline Insight: Osteoporosis - Intermittent Dosing
and Multiple Indications Drive Market Growth 28-Jan-2004
Analysis of the
osteoporosis pipeline providing detailed profiles of late stage drug
candidates, benchmarks these against gold standard products and
includes sales forecasts to
2011.
-------------------------------------------------------------------------------------------------------------------------
|
92- Stakeholder Insight: Atrial Fibrillation - Future
Advances in Stroke Prevention 23-Jan-2004
Based on 180
physician interviews across seven major markets, this report
analyzes the current and future trends in the management and
treatment of atrial fibrillation and the prevention of stroke in
this
population.
-------------------------------------------------------------------------------------------------------------------------
|
93- Stakeholder Insight: Invasive Fungal Infections -
Options Outweigh Replacements 20-Jan-2004
Assessment of
antifungal treatment practices in hospitals across the seven major
markets.
-------------------------------------------------------------------------------------------------------------------------
|
94- Mobile Enterprise Solutions: Assessing the Market
Opportunities for the Pharmaceutical Industry 19-Jan- 2004
Mobile
Enterprise Solutions provides an overview of the current and
prospective enterprise mobile device market. The wide variety of
mobile devices available to enterprises is examined as are the two
divergent perceptions of enterprise
mobility.
-------------------------------------------------------------------------------------------------------------------------
|
95- Stakeholder Insight: Dyslipidemia - Titration versus
Combination Therapy 19-Jan-2003
Based on 180
physician interviews across seven major markets, this report
analyzes the current and future trends in the management and
treatment of dyslipidemia and dyslipidemia sub-populations,
including mixed and diabetic
dyslipidemia.
-------------------------------------------------------------------------------------------------------------------------
|
96- Harnessing Patient Power: Strategies for
speeding drug approval, building and retaining market
share Jan-2004
The report uses detailed case studies to pinpoint how
pharma companies can convert such relationships into important
business tools to meet their corporate objectives.
.
-------------------------------------------------------------------------------------------------------------------------
|
97- Therapeutic Vaccines: Strong Innovation But Far Away
From Capitalization 25-Dec-2003
A comprehensive
evaluation of the global therapeutic vaccine market, encompassing
market dynamics, company strategy and comparative benchmarking of
the development programs of 65 players by technology and therapy
area.
-------------------------------------------------------------------------------------------------------------------------
|
98- Therapeutic Antibodies: Capitalizing on the Fully
Human Wave 9-Dec-2003
Use this report to benchmark your position within the
antibody market and identify the optimum strategy for future
technological and supply chain management..
-------------------------------------------------------------------------------------------------------------------------
|
99- Japanese Pharma to 2008: Innovation and Expansion Will
Counter the Western Threat 1-Dec-2003
Benchmarks leading Japanese pharma companies,
evaluating their strategic direction, marketed portfolios and
R&D pipeline, with product, therapy area and company forecasts
to
2008.
-------------------------------------------------------------------------------------------------------------------------
|
100- Optimizing Promotional Alliances: Benchmarking
Co-marketing and Co-promotion Strategies in the Pharmaceutical
Industry 24-Nov-2003
An indepth review of co-promotion and co-marketing
agreements between July 2001 and July 2003, providing insight into
deal value and structure. Co-commercialization trends within the
industry are also evaluated with licensing opportunities in
mind.
-------------------------------------------------------------------------------------------------------------------------
|
101- Pharmaceutical Portfolio Management: Strategies to
Deliver Corporate Success 18-Nov-2003
Portfolio
management in the implementation and development of corporate
strategy, communications and driving growth - the tools and
processes required for effective portfolio management and current
industry
practice.
-------------------------------------------------------------------------------------------------------------------------
|
102- The Lifestyle Drugs Outlook to 2008: Unlocking new
value in well-being
3-Oct-2003
This report can
help you to assess the premium associated with different lifestyle
drug markets and identify the potential for higher volume
sales.
--------------------------------------------------------------------------------------------------------------------------
|
103- The DTC Marketing Outlook: New challenges and
opportunities in consumer-targeted pharmaceutical
promotion
30-Sep-2003
This new report will show you how by empowering
consumers with disease and product information utilizing effective
DTC marketing techniques, you will see improvements in ROI,
branding, consumer attention and product
awareness.
-------------------------------------------------------------------------------------------------------------------------
|
| |
| |
| |
